Therefore, the use of system Xc− selective inhibitors or TFR1 agonists to treat MYCN-amplified neuroblastoma will increase the level of lipid peroxidation and eventually lead to ferroptosis of tumor cells (Figure 1). Here, TFRC is linked to neuroblastoma.